Mucosal healing in inflammatory bowel diseases: a systematic review.

PubWeight™: 3.02‹?› | Rank: Top 1%

🔗 View Article (PMID 22842618)

Published in Gut on July 27, 2012

Authors

Markus F Neurath1, Simon P L Travis

Author Affiliations

1: Professor of Medicine, Department of Medicine I, University of Erlangen-Nuremberg, Ulmenweg 18, Erlangen, Germany. markus.neurath@uk-erlangen.de

Associated clinical trials:

Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease (BioIBD) | NCT03885713

Articles citing this

(truncated to the top 100)

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med (2014) 2.54

The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol (2015) 2.51

Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci (2014) 1.48

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44

Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42

New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25

Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.15

Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09

Wound repair: role of immune-epithelial interactions. Mucosal Immunol (2015) 1.00

Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis. Gastroenterol Res Pract (2013) 0.99

Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr (2013) 0.96

Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2014) 0.96

Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol (2015) 0.95

M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative colitis. PLoS One (2013) 0.95

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol (2015) 0.93

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy? World J Stem Cells (2015) 0.93

Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol (2015) 0.93

Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol (2014) 0.92

Polyphenol-Rich Propolis Extracts Strengthen Intestinal Barrier Function by Activating AMPK and ERK Signaling. Nutrients (2016) 0.90

Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J Nutr Biochem (2014) 0.89

Sacral nerve stimulation enhances early intestinal mucosal repair following mucosal injury in a pig model. J Physiol (2016) 0.89

The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Sci (2014) 0.88

Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol (2016) 0.87

Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol (2014) 0.87

Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol (2015) 0.87

Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol (2015) 0.87

Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.85

Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. Gastroenterol Rep (Oxf) (2015) 0.85

Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) (2014) 0.84

Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.84

Prohibitin 1 modulates mitochondrial function of Stat3. Cell Signal (2014) 0.84

Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J (2014) 0.83

Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci (2014) 0.82

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol (2016) 0.82

Immune-epithelial crosstalk at the intestinal surface. J Gastroenterol (2014) 0.81

The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81

Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol (2015) 0.80

Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. Am J Pathol (2015) 0.80

Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats. Int J Nanomedicine (2014) 0.80

Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology (2016) 0.80

The current and future role of endomicroscopy in the management of inflammatory bowel disease. Ann Gastroenterol (2015) 0.80

Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med (2015) 0.79

Beyond white light endoscopy: the role of optical biopsy in inflammatory bowel disease. World J Gastroenterol (2013) 0.79

Autophagy Contributes to the Induction of Anti-TNF Induced Macrophages. J Crohns Colitis (2015) 0.79

Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. Clin Exp Gastroenterol (2014) 0.79

Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm (2013) 0.79

Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci (2014) 0.78

Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. Redox Biol (2013) 0.78

Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem (2014) 0.78

Conflicting results on the efficacy of enteral nutrition during infliximab maintenance therapy for Crohn's disease are correct. Dig Dis Sci (2013) 0.78

Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J (2014) 0.78

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS One (2016) 0.78

A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract (2016) 0.78

Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther (2017) 0.77

Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol (2015) 0.77

Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J Pharmacol Exp Ther (2014) 0.77

Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One (2016) 0.77

Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol (2014) 0.77

Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol (2016) 0.77

Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease. Intest Res (2016) 0.76

"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol (2014) 0.76

Nilotinib-mediated mucosal healing in a rat model of colitis. World J Gastroenterol (2013) 0.76

Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease. Yonsei Med J (2014) 0.76

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis (2017) 0.75

AGR2 ameliorates tumor necrosis factor-α-induced epithelial barrier dysfunction via suppression of NF-κB p65-mediated MLCK/p-MLC pathway activation. Int J Mol Med (2017) 0.75

Regenerating Reputations: Are Wnt and Myc the Good Guys After All? Dig Dis Sci (2016) 0.75

Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.75

The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response. Gastroenterol Res Pract (2015) 0.75

Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging. Sci Rep (2016) 0.75

Spontaneous seromuscular laceration of the sigmoid colon: a case report. Clin Case Rep (2015) 0.75

The Epithelial Sodium Channel and the Processes of Wound Healing. Biomed Res Int (2016) 0.75

Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore) (2016) 0.75

From the surface to the single cell: Novel endoscopic approaches in inflammatory bowel disease. World J Gastroenterol (2015) 0.75

Ulcerative colitis: UCCIS--a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol (2012) 0.75

Light and sound - emerging imaging techniques for inflammatory bowel disease. World J Gastroenterol (2016) 0.75

Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol (2016) 0.75

Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis (2016) 0.75

Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism. Sci Rep (2017) 0.75

Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa? Nutrients (2017) 0.75

Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) (2016) 0.75

M1 Macrophages Activate Notch Signalling in Epithelial Cells: Relevance in Crohn's Disease. J Crohns Colitis (2016) 0.75

Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. World J Gastroenterol (2016) 0.75

Evaluation of disease extent with the Crohn's disease endoscopic index of severity. Gut (2013) 0.75

Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol (2016) 0.75

Aligning oral mesalazine treatment to health service priorities: guidance for nurses. Frontline Gastroenterol (2013) 0.75

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol (2017) 0.75

Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc (2016) 0.75

Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc (2016) 0.75

Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open (2017) 0.75

Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World J Gastroenterol (2017) 0.75

The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res (2016) 0.75

The role of colonoscopy in inflammatory bowel disease. Clin Endosc (2013) 0.75

Structural and molecular features of intestinal strictures in rats with Crohn's-like disease. World J Gastroenterol (2016) 0.75

A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation. Sci Rep (2016) 0.75

A Retrospective Evaluation of the Utility of Capsule Endoscopy and Double-Balloon Endoscopy in Crohn's Disease. Gastroenterol Res Pract (2015) 0.75

Development and Application of a Plant-Based Diet Scoring System for Japanese Patients with Inflammatory Bowel Disease. Perm J (2016) 0.75

MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase/Akt signalling pathway. Int J Mol Med (2017) 0.75

Histologic Normalization Occurs in Ulcerative Colitis and is Associated with Improved Clinical Outcomes. Clin Gastroenterol Hepatol (2017) 0.75

Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease. Pediatr Radiol (2017) 0.75

Articles by these authors

Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut (2012) 4.24

Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut (2010) 2.82

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol (2010) 1.74

TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology (2006) 1.73

Weight loss at high altitude: pathophysiology and practical implications. Eur J Gastroenterol Hepatol (2006) 1.68

A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet (2005) 1.65

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62

Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. J Crohns Colitis (2008) 1.28

A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut (2012) 1.16

Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol (2011) 1.16

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15

The pattern and outcome of acute severe colitis. J Crohns Colitis (2010) 1.06

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum (2006) 1.01

The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis (2009) 1.00

Medical management of Crohn's disease. BMJ (2008) 0.97

Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev (2013) 0.95

Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion (2012) 0.89

Biosimilars in IBD: hope or expectation? Gut (2013) 0.88

Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol (2003) 0.86

Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion (2011) 0.86

Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 0.85

What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv (2012) 0.85

The European consensus on ulcerative colitis: new horizons? Gut (2008) 0.83

Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol (2005) 0.82

How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets (2010) 0.79

Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol (2008) 0.79

Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol (2015) 0.78

Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.77

Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. J Crohns Colitis (2008) 0.77

An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis (2008) 0.76

Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.76

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis (2009) 0.76

Acute upper gastrointestinal bleeding: identifying low risk patients. Gut (2012) 0.75

Causality and Chance in the Development of Cancer. N Engl J Med (2015) 0.75

IBD and IBS: novel mechanisms and future practice. Preface. Dig Dis (2010) 0.75

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 0.75